Pentoxifylline after lower limb endovascular therapy in diabetic foot with severe ischemia

Phase 4, randomised, open-label trial of pentoxifylline and cilostazol in diabetic foot syndrome and arteriosclerosis obliterans (3 arms), sponsored by Zhu Xianyi Memorial Hospital. Primary endpoints: Patency of artery in lower extremity, Maintaining time of patency of artery in lower extremity and 3 more. Planned start Sep 2021; status: not yet recruiting.